Oxidative DNA damage is associated with inflammatory response, insulin resistance and microvascular complications in type 2 diabetes

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 782, Issue , 2015, Pages 17-22

  Tatsch, Etiane ^a   Carvalho, José A M De ^a,b   Hausen, Bruna S ^a   Bollick, Yãnaí S ^a   Torbitz, Vanessa D ^a   Duarte, Thiago ^a   Scolari, Rogério ^c   Duarte, Marta M M F ^c,d   Londero, Sílvia W K ^b   Vaucher, Rodrigo A ^e   Premaor, Melissa O ^a   Comim, Fabio V ^a   Moresco, Rafael N ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b University Hospital   (Brazil)

^c Labimed Clinical Chemistry and Medicine Laboratory   (Brazil)

^d UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^e CENTRO UNIVERSITÁRIO FRANCISCANO   (Brazil)

Author keywords

DNA damage; Inflammation; Insulin resistance; Type 2 diabetes

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; BIOLOGICAL MARKER; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; 8-OXO-7-HYDRODEOXYGUANOSINE; CYTOKINE; DEOXYGUANOSINE;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DNA DAMAGE; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; DIABETIC ANGIOPATHY; GENETICS; IMMUNOLOGY; MICROVASCULATURE; MIDDLE AGED; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL; URINE;

BIOMARKERS; CASE-CONTROL STUDIES; CYTOKINES; DEOXYGUANOSINE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DNA DAMAGE; FEMALE; HUMANS; INSULIN RESISTANCE; LINEAR MODELS; MALE; MICROVESSELS; MIDDLE AGED; OXIDATIVE STRESS; ROC CURVE;

EID: 84945559068     PISSN: 00275107     EISSN: 18792871     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2015.10.003     Document Type: Article

References (52)

1. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
2. Rains J.L., Jain S.K. Oxidative stress, insulin signaling, and diabetes. Free Radic. Biol. Med. 2011, 50:567-575.
3. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 2011, 11:98-107.
4. Leahy J.L. Pathogenesis of type 2 diabetes. Arch. Med. Res. 2005, 36:197-209.
5. Wu L.L., Chiou C., Chang P., Wu J.T. Urinary 8-OHdG: a marker of oxidative stress to DNA and risk factor for cancer, atherosclerosis and diabetics. Clin. Chim. Acta 2004, 339:1-9.
6. Pan H., Zhang L., Guo M., Sui H., Li H., Wu W., Qu N., Liang M., Chang D. The oxidative stress status in diabetes mellitus and diabetic nephropathy. Acta Diabetol. 2010, 47:S71-S76.
7. Xu G.W., Yao Q.H., Weng Q.F., Su B.L., Zhang X., Xiong J.H. Study of urinary 8-hydroxydeoxyguanosine as a biomarker of oxidative DNA damage in diabetic nephropathy patients. J. Pharm. Biomed. Anal. 2004, 36:101-104.
8. Broedbaek K., Siersma V., Henriksen T., Weimann A., Petersen M., Andersen J.T., Jimenez-Solem E., Hansen L.J., Henriksen J.E., Bonnema S.J., Olivarius N., Poulsen H.E. Association between urinary markers of nucleic acid oxidation and mortality in type 2 diabetes. Diabetes Care 2013, 36:669-676.
9. Al-Aubaidy H.A., Jelinek H.F. 8-Hydroxy-2-deoxy-guanosine identifies oxidative DNA damage in aa rural prediabetes cohort. Redox Rep. 2010, 15:155-160.
10. Association American Diabetes Standards of medical care in diabetes. Diabetes Care 2014, 37:S14-S80.
11. Matheson A., Willcox M.D.P., Flanagan J., Walsh B.J. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes Metab. Res. Rev. 2010, 26:150-171.
12. Barratt J., Tophan P. Urine proteomics: the present and future of measuring urinary protein components in disease. Can. Med. Assoc. J. 2007, 177:361-368.
13. Tatsch E., Bochi G.V., Piva S.J., De Carvalho J.A.M., Kober H., Torbitz V.D., Duarte T., Signor C., Coelho A.C., Duarte M.M.M.F., Montagner G.F.F.S., Da Cruz I.B.M., Moresco R.N. Association between DNA strand breakage and oxidative, inflammatory and endothelial biomarkers in type 2 diabetes. Mutat. Res. 2012, 732:16-20.
14. Akash M.S.H., Rehman K. S, Chen, Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. J. Cell. Biochem. 2013, 114:525-531.
15. Pandey K.B., Mishra N., Rizvi S.I. Protein oxidation biomarkers in plasma of type 2 diabetic patients. Clin. Biochem. 2010, 43:508-511.
16. Alderman C., Shah S., Foreman J.C., Chain B.M., Katz D.R. The role of advanced oxidation protein products in regulation of dentritic cell function. Free Radic. Biol. Med. 2002, 32:377-385.
17. Witko-Sarsat V., Gausson V., Nguyen A.T., Touam M., Drüeke T., Santangelo F., Descamps-Latscha B. AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int. 2003, 64:82-91.
18. Saxena M., Srivastava N., Banerjee M. Association of IL-6, TNF-α and IL-10 gene polymorphisms with type 2 diabetes mellitus. Mol. Biol. Rep. 2013, 40:6271-6279.
19. Mayfiled J.E., Sugarman J.R. The use of semmens-Weinstein monofilament and other threshold tests for preventing foot ulceration and amputation in people with diabetes. J. Fam. Pract. 2000, 49:S17-S29.
20. Hanasand M., Omdal R., Norheim K.B., Goransson L.G., Brede C., Jonsson G. Improved detection of advanced oxidation protein products in plasma. Clin. Chim. Acta 2012, 413:901-906.
21. Newman D.J., Pugia M.J., Lott J.A., Wallace J.F., Hiar A. Urinary protein and albumin excretion corrected by creatinine and specific gravity. Clin. Chim. Acta 2000, 294:139-155.
22. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., Feldman H.I., Kusek J.W., Eggers P., Van Lente F., Greene T., Coresh J. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 2009, 150:604-612.
23. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
24. Shin C.S., Moon B.S., Park K.S., Kim S.Y., Park S.J., Chung M.H., Lee H.K. Serum 8-hydroxy-guanine levels are increased in diabetic patients. Diabetes Care 2001, 24:733-737.
25. Broedbaek K., Weimann A., Stovgaard E.S., Poulsen H.E. Urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine as a biomarker in type 2 diabetes. Free RadicBiol 2011, 51:1473-1479.
26. Yang H., Jin X., Kei Lam C.W., Yan S.K. Oxidative stress and diabetes mellitus. Clin. Chem. Lab. Med. 2011, 49:1773-1782.
27. Iĺyasova D., Scarbrough P., Spasojevic I. Urinary biomarkers of oxidative status. Clin. Chim. Acta 2012, 413:1446-1453.
28. Nishikawa T., Sasahara T., Kiritoshi S., Sonoda K., Senokuchi T., Matsuo T., Kukidome D., Wake N., Matsumura T., Miyamura N., Sakakida M., Kishikawa H., Araki E. Evaluation of urinary 8-hydroxydeoxyguanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care 2003, 26:1507-1512.
29. Serdar M., Sertoglu E., Uyanik M., Tapan S., Akin K., Bilgi C., Kurt I. Comparison of 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels using mass spectrometer and urine albumin creatinine ratio as a predictor of development of diabetic nephropathy. Free Radic. Res. 2012, 46:1291-1295.
30. Dong Q.Y., Cui Y., Chen L., Song J., Sun L. Urinary 8-hydroxydeoxyguanosine levels in diabetic retinopathy patients. Eur. J. Ophthalmol. 2008, 18:94-98.
31. Brodsky S.V., Gealekman O., Chen J., Zhang F., Togashi N., Crabtree M., Gross S.S., Nasjletti A., Goligorsky M.S. Prevention and reversal of premature endothelial cell senescence and vasculopathy in obesity-induced diabetes by ebselen. Circ. Res. 2004, 94:377-384.
32. Shimizu I., Yoshida Y., Suda M., Minamino T. DNA damage response and metabolic disease. Cell Metab. 2014, 20:967-977.
33. Erusalimsky J.D. Vascular endothelial senescence: from mechanisms to pathophysiology. J. Appl. Physiol. 2009, 106:326-332.
34. Sliwinska A., Blasiak J., Kasznicki J., Drzewoski J. In vitro effect of gliclazide on DNA damage and repair in patients with type 2 diabetes mellitus (T2DM). Chem. Biol. Interact. 2008, 173:159-165.
35. Al-Aubaidy H.A., Jelinek H.F. Oxidative DNA damage and obesity in type 2 diabetes mellitus. Eur. J. Endocrinol. 2011, 164:899-904.
36. Komosinska-Vassev K., Olczyk K., Olczyk P., Winsz-Szczotka K. Effects of metabolic control and vascular complications on indices of oxidative stress in type 2 diabetic patients. Diabetes Res. Clin. Pract. 2005, 68:207-216.
37. Esser N., Legrand-Poels S., Piette J., Scheen A.J., Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res. Clin. Pract. 2014, 105:141-150.
38. Grossmann V., Schmitt V.H., Zeller T., Panova-Noeva M., Schulz A., Laubert-Reh D., Juenger C., Schnabel R.B., Abt T.G.J., Laskowski R., Wiltink J., Schulz E., Blankenberg S., Lackner K.J., Münzel T., Wils P.S. Profile of the immune and inflammatory response in individuals with prediabetes and type 2 diabetes. Diabetes Care 2015, 38:1356-1364.
39. Donath M.Y., Böni-Schnetzler M., Ellingsgaard H., Halban P.A., Ehses J.A. Cytokine production by islets in health and diabetes: cellular origin, regulation and function. Trends Endocrinol. Metab. 2010, 21:261-267.
40. Michima Y., Kuyama A., Tada A., Takahashi K., Ishioka T., Kibata M. Relationship between sérum tumor necrosis fator-α and insulin resistance in obese men with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2001, 52:119-123.
41. Van Exel E.V., Gussekloo J., Craen A.J.M., Frolich M., Wiel A.B., Westendorp R.G.J. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes. Diabetes 2002, 51:1088-1092.
42. Banerjee M., Saxena M. Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes. Clin. Chim. Acta 2012, 413:1163-1170.
43. Li J., Wu S., Wang M., Wang T., Zhu J. Association of the interleukin-10-592A/C, -1082G/A and -819T/C gene polymorphisms with type 2 diabetes: a meta-analysis. Gene 2013, 521:211-216.
44. Tilg H., Moschen A.R. Inflammatory mechanisms in the regulation of insulin resistance. Mol. Med. 2008, 14:222-231.
45. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
46. Herder C., Carstensen M., Ouwens D.M. Anti-inflammatory cytokines and risk of type 2 diabetes. Diabetes Obes. Metab. 2013, 13:39-50.
47. Cooke M.S., Olinski R., Evans M.D. Does measurement of oxidative damage to DNA have clinical significance?. Clin. Chim. Acta 2006, 365:30-49.
48. Kalousová M., Skrha J., Zima T. Advanced Glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol. Res. 2002, 51:597-604.
49. Piwowar A., Knapik-Kordecka M., Warwas M. AOPP and its relations with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2007, 77:188-192.
50. Bansal S., Chawla D., Siddarth M., Banerjee B.D., Madhu S.V., Tripathi A.K. A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications. Clin. Biochem. 2013, 46:109-114.
51. Prütz W.A. Interactions of hypochlorous acid with pyrimidine nucleotides, and secondary reactions of chlorinated pyrimidines with GSH, NADH, and other substrates. Arch. Biochem. Biophys. 1998, 349:183-191.
52. Asahi T., Kondo H., Masuda M., Nishino H., Aratani Y., Naito Y., Yoshikawa T., Hisaka S., Kato Y., Osawa T. Chemical and immunochemical detection of 8-halogenated deoxyguanosines at early stage inflammation. J. Biol. Chem. 2010, 285:9282-9291.